Casdin Capital’s Standard BioTools LAB Stock Holding History

Casdin Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73M	Hold	88,783,856	–	–	3.66%	6
2026 Q1	$81.6M	Hold	88,783,856	–	–	6.18%	5
2025 Q4	$114M	Buy	88,783,856 +11,225,000	+14%	+$15.1M	7.06%	4
2025 Q3	$101M	Buy	77,558,856 +1,483,220	+2%	+$1.94M	8.41%	4
2025 Q2	$91.3M	Hold	76,075,636	–	–	8.31%	4
2025 Q1	$82.2M	Buy	76,075,636 +4,820,959	+7%	+$6.77M	6.71%	4
2024 Q4	$125M	Hold	71,254,677	–	–	8.3%	5
2024 Q3	$138M	Buy	71,254,677 +7,295,000	+11%	+$14.3M	9.17%	4
2024 Q2	$113M	Buy	63,959,677 +2,052,072	+3%	+$5.02M	8.64%	4
2024 Q1	$168M	Buy	61,907,605 +60,707,605	+5,059%	+$147M	12.47%	2
2023 Q4	$2.65M	Hold	1,200,000	–	–	0.26%	33
2023 Q3	$3.48M	Hold	1,200,000	–	–	0.39%	30
2023 Q2	$2.32M	Buy	+1,200,000	New	+$2.37M	0.2%	34

Other funds holding LAB

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Casdin Capital's LAB Position: Q2 2026 in Review

Casdin Capital held its Standard BioTools (LAB) position steady in Q2 2026 at 88,783,856 shares worth $73M. The position accounts for 3.66% of the portfolio, ranked #6.

Casdin Capital first reported a position in LAB in Q2 2023 and has held it in 13 quarters since. The position peaked at $168M in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Casdin Capital held 88,783,856 shares of Standard BioTools worth $73M as of Q2 2026.
Casdin Capital left its Standard BioTools share count unchanged in Q2 2026.
Standard BioTools made up 3.66% of Casdin Capital's portfolio in Q2 2026, its #6 holding.
Casdin Capital first reported a position in Standard BioTools in Q2 2023 and has held it in 13 quarters since.
Casdin Capital's Standard BioTools position peaked at $168M in Q1 2024.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.